Bootstrap aggregating continual reassessment method for dose finding in drug-combination trials

DOI10.1214/16-AOAS982zbMATH Open1454.62351MaRDI QIDQ512445FDOQ512445

Authors: Ruitao Lin, Guosheng Yin 

Publication date: 24 February 2017

Published in: The Annals of Applied Statistics (Search for Journal in Brave)

Recommendations

• Bayesian dose finding for combined drugs with discrete and continuous doses
• A Bayesian dose-finding design for drug combination trials with delayed toxicities
• A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents
• Bayesian phase I/II adaptively randomized oncology trials with combined drugs
• Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials

zbMATH Keywords

dimension reductionBayesian model averagingmaximum tolerated dosebaggingdrug combination

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cited In (4)

• Evaluation of phase I clinical trial designs for combinational agents along with guidance based on simulation studies
• Flexible use of copula‐type model for dose‐finding in drug combination clinical trials
• A nonparametric Bayesian method for dose finding in drug combinations cancer trials
• Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials

This page was built for publication: Bootstrap aggregating continual reassessment method for dose finding in drug-combination trials

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q512445)